The Drug Safety Research Unit (DSRU) is an independent academic unit internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training Services for over 30 years.
In partnership with doctors in England, the DSRU, led by Director Professor Saad Shakir, aims to protect patients in primary and specialist care from unwanted adverse effects of newly marketed medicines using our unique methods of monitoring patients during the lifecycle of medicines.
The ROSE-ACS team attended the British Cardiovascular society annual conference at Manchester Central between the 6-8th June 2016. The annual conference welcomes over 2,600 delegates and 30 exhibitors each year. The theme of the conference was “Prediction and Prevention” and the three days consisted of several talks and presentations on “Big data; a big deal for cardiology”, “Elucidating the genetic basis of coronary artery disease; implications for prediction, prevention and treatment”, “Prediction and prevention in acute coronary syndromes” and “Prediction and prevention of sudden cardiac death in the young”.
The ROSE-ACS team had their own exhibitor stand and received a steady flow of interested parties including cardiologists, cardiac and research nurses. It sparked a variety of discussions and debates especially around the use of Rivaroxaban in acute coronary syndrome. The team were able to distribute ROSE-ACS study information which we hope will inspire more healthcare professionals to enquire further and maybe consider taking part.
For more information on our study, click here.View our latest news
The Drug Safety Research Unit (DSRU) offers a range of Pharmacovigilance (PV) training courses suitable for those looking for a career in pharmacovigilance, seeking career progression or in a position that requires PV knowledge and understanding. Depending on specific interests and current knowledge, the team at the DSRU is able to recommend which of our training courses could help […]View all our latest questions